Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know.
Acta Neurochir (Wien)
; 166(1): 261, 2024 Jun 11.
Article
en En
| MEDLINE
| ID: mdl-38858236
ABSTRACT
PURPOSE:
The gold standard for diagnostics in primary central nervous system lymphoma (PCNSL) is histopathological diagnosis after stereotactic biopsy. Yet, PCNSL has a multidisciplinary diagnostic work up, which associated with diagnostic delay and could result in treatment delay. This article offers recommendations to neurosurgeons involved in clinical decision-making regarding (novel) diagnostics and care for patients with PCNSL with the aim to improve uniformity and timeliness of the diagnostic process for patients with PCNSL.METHODS:
We present a mini review to discuss the role of stereotactic biopsy in the context of novel developments in diagnostics for PCNSL, as well as the role for cytoreductive surgery.RESULTS:
Cerebrospinal fluid-based diagnostics are supplementary and cannot replace stereotactic biopsy-based diagnostics.CONCLUSION:
Histopathological diagnosis after stereotactic biopsy of the brain remains the gold standard for diagnosis. Additional diagnostics should not be a cause of diagnostic delay. There is currently no sufficient evidence supporting cytoreductive surgery in PCNSL, with recent studies showing contradictive data and suboptimal study designs.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Sistema Nervioso Central
/
Diagnóstico Tardío
/
Tiempo de Tratamiento
/
Linfoma
Límite:
Humans
Idioma:
En
Revista:
Acta Neurochir (Wien)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Países Bajos